nyc uxpa: wud 2013 - shawn blackburn (part 3)

6
90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 00 | 01 | 02 | 03 | 04 | 05 | 06 | 07 | 08 | 09 | 10 | 11 | 12 | 13 CONSTRUCTION SOFTWARE PROGRAMMER Y PRIME BUSINESS FOUNDATIONS Shawn started his career in business founding a construction company in the early 1990s. CAREER CHANGE After over 10 years in the construction business Shawn changed career paths and became a database programmer in the financial services industry. DEVELOPMENT & CONSULTING Since 2000 Shawn has continued to advance in the career of software development and software consulting. LEADING GROWTH Since 2006 Shawn has lead the growth of Y Prime to become a premier company with products and services that support many top 50 Pharma companies. SHAWN BLACKBURN CEO Y PRIME

Upload: nycuxpa

Post on 08-Jul-2015

103 views

Category:

Technology


3 download

DESCRIPTION

Part 3 of a 6-person panel for NYC UXPA's World Usability Day 2013 - Healthcare: Collaborating for Better Systems.

TRANSCRIPT

Page 1: NYC UXPA: WUD 2013 - Shawn Blackburn (Part 3)

’90 | ’91 | ‘92 | ‘93 | ‘94 | ‘95 | ‘96 | ‘97 | ‘98 | ‘99 | ‘00 | ‘01 | ‘02 | ‘03 | ’04 | ‘05 | ‘06 | ‘07 | ‘08 | ‘09 | ‘10 | ‘11 | ‘12 | ‘13

CONSTRUCTION

SOFTWARE PROGRAMMER

Y PRIME

BUSINESS FOUNDATIONSShawn started his career in business

founding a construction company in the

early 1990s.

CAREER CHANGEAfter over 10 years in the construction

business Shawn changed career paths

and became a database programmer

in the financial services industry. DEVELOPMENT & CONSULTINGSince 2000 Shawn has continued to advance in the

career of software development and software consulting.

LEADING GROWTHSince 2006 Shawn has lead the growth of Y Prime to

become a premier company with products and services

that support many top 50 Pharma companies.

SHAWN BLACKBURN – CEO Y PRIME

Page 2: NYC UXPA: WUD 2013 - Shawn Blackburn (Part 3)

PHASE

I

CLINICAL TRIAL PROCESS

PHASE

II

PHASE

III

PHASE

IV

Determine the metabolic

and pharmacological

actions & the maximally

tolerated dose

Evaluateeffectiveness, determine

short-term side effects &

identify common risks for a

specific population and

disease

Obtain additional info

about the effectiveness on

clinical outcomes &

evaluate the overall risk-

benefit ratio in a

demographically diverse

sample

Monitor ongoing safety in

large population & identify

additional uses of the agent

that might be approved by

the FDA

1-888-201-7988 @y_primewww.y-prime.com [email protected]

Page 3: NYC UXPA: WUD 2013 - Shawn Blackburn (Part 3)

Researchers

Finance Managers

Statisticians

Physicians

Surgeons

Pharmacists

Nurses

Study Coordinators

Administrators

Data Analysts

Lawyers

Scientists

Information Technology

Patients

{ Many disciplines are involved in the process }

HUMAN ELEMENTS OF CLINICAL TRIALS

Page 4: NYC UXPA: WUD 2013 - Shawn Blackburn (Part 3)

MULTIPLE SOFTWARE SYSTEMS

Page 5: NYC UXPA: WUD 2013 - Shawn Blackburn (Part 3)

Clinical research professionals operate within a controlled

industry requiring continual monitoring of many regulations

• Protocols

• SOPs

• Work Instructions

• Training

All in addition to actually doing their day jobs…

Working with Patients

HIGHLY REGULATED DATA

Page 6: NYC UXPA: WUD 2013 - Shawn Blackburn (Part 3)

OUR CHALLENGE

SOFTWARE LIVEWARE UXHARDWARE